Rituximab Ups Survival in Chronic Lymphocytic Leukemia (CLL), University of Cologne Study

Published: Oct 01, 2010

MedPageToday -- Adding the monoclonal antibody rituximab (Rituxan) to initial chemotherapy significantly improved progression-free and overall survival in patients with chronic lymphocytic leukemia (CLL), a prospective study found.

Back to news